Saturday, August 13, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Advancing Therapeutic Discovery for Select Resistant Gram-Negative Bacteria

by Global Biodefense Staff
April 26, 2017
Biosecurity Research Programs

Image: HMS (iStock).

In response to the threat presented by increasing numbers of infections caused by antimicrobial–resistant (AR) and multidrug-resistant (MDR) Gram-negative bacterial pathogens, the NIAID Division of Microbiology and Infectious Diseases (DMID) has established research programs to facilitate development of therapeutics targeting select pathogens.

Under a new Funding Opportunity Announcement (FOA), NIAID DMID is inviting applications for milestone-driven research projects focused on development and utilization of novel predictive assays, models and/or research tools based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Enterobacteriaceae (CRE), MDR Acinetobacter and/or MDR Pseudomonas aeruginosa.

The objective of this FOA is to support milestone-driven projects focused on developing and utilizing novel predictive models and/or research tools and assays aimed at gaining a better understanding of the rules and compound properties governing the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens.

Responsive projects must focus on one or more of the following Gram-negative bacterial pathogens: carbapenem-resistant Enterobacteriaceae (CRE), MDR Acinetobacter and/or MDR Pseudomonas aeruginosa. Projects must complete assay/tool/model development prior to the end of the third year of the project period and initiate discovery activities to demonstrate its utility in supporting a corresponding medicinal chemistry program to generate a lead chemical series with demonstrated activity against one or more targeted Gram-negative bacteria.

This initiative will also support subsequent preclinical development of a promising lead antibacterial.

Examples of assay and model development include, but are not limited to:

  • Quantitative cellular (or model system) assays to measure drug penetration and efflux, independent from standard MIC testing
  • Innovative quantitative assays to measure drug concentrations in bacterial cytoplasm and/or periplasmic space
  • Innovative technologies for assessment of the kinetics of drug penetration and efflux from bacteria
  • Computational algorithms for describing/predicting physical-chemical properties or guidelines needed by small molecules for optimal Gram-negative penetration and efflux avoidance.

Successful projects will demonstrate the utility of the developed tools/assays to predict and measure potency of candidate therapeutics against Gram-negative targets. Preferably, this will be accomplished by using the developed models or assays to guide a medicinal chemistry campaign aimed at producing a novel chemical series with Gram-negative activity; or by screening existing libraries using the computational algorithms developed as a tool to find compounds with Gram-negative activity.

Alternatively, the utility of the developed tools/assays can be demonstrated by profiling existing libraries of compounds with known Gram-negative activity.

Further details are available via RFA-AI-16-081. The application deadline is May 18, 2017.

Tags: AntimicrobialsNIAIDRequest for Proposals

Related Posts

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
Poxvirus Proteins Enable Early Strike on Immune Defences
Pathogens

Poxvirus Proteins Enable Early Strike on Immune Defences

July 15, 2022
Targeting Poxviruses with Messenger RNA Technology
Medical Countermeasures

Targeting Poxviruses with Messenger RNA Technology

July 11, 2022
Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC